Antiverse raises $9.3M Series A to scale AI-driven antibody discovery from Cardiff

The Next WebPublished Mar 3, 2026

Antiverse secured $9.3 million in Series A funding to advance its AI-driven platform for discovering antibodies, aiming to accelerate drug development from its base in Cardiff.

#antibody-discovery #antiverse #cardiff #drug-development #series-a-funding

Antiverse raises $9.3M Series A to scale AI-driven antibody discovery from Cardiff

More in Healthcare

AI-Driven Inventory Optimization As An Operating Model Framework

Healthcare AI Agents Are Here—The Hugging Face Hack Shows Why They Need Guardrails

Machine learning dataset and benchmark for accurate T cell receptor–pHLA binding prediction